The company operates a pipeline of bispecific and antibody-drug conjugate candidates targeting tumor-associated antigens and immune checkpoint molecules, including lorigerlimab, MGC026, and MGC028. MacroGenics leverages proprietary Fc engineering and Dual Activating ReTargeting technology to improve antibody functions and eliminate cancer cells.
Cyborg Score Rationale
The company faces significant financial distress with an Altman Z-Score of -5.61 indicating potential bankruptcy risk within two years. Recent FDA setbacks include a partial clinical hold on lorigerlimab's Phase 2 LINNET study with serious safety events. Large ongoing losses and significant cash burn increase financing risk.
Top Insights
FDA placed partial clinical hold on lorigerlimab Phase 2 trial in February 2026 due to serious safety events including thrombocytopenia, myocarditis, and fatal septic shock in 41 participants
Company had $146.4M in cash and marketable securities as of Sept 2025, with expected partnering payments extending runway into late 2027